A Glimpse Into The Future Of Dementia Care

WEB Quest Launches Breakthrough Alzheimer's Risk Assessment Test

A Glimpse into the Future of Dementia Care

WEB Quest Diagnostics, a leading provider of diagnostic information services, has revolutionized the approach to Alzheimer's disease care. With the launch of their innovative AD-Detect Beta-Amyloid 4240 Ratio test, they are empowering individuals to take a proactive role in their health journey.

The Quest for Precision

The beta-amyloid 4240 ratio measures levels of two beta-amyloid proteins, Aβ42 and Aβ40, which are abnormal in individuals with Alzheimer's disease. By assessing this ratio, the test can indicate the presence of potential amyloid plaque formation in the brain, a hallmark of the disease.

Changing the Alzheimer's Landscape

This advancement comes amidst a rapidly evolving landscape for Alzheimer's disease care. With new and emerging therapies on the horizon, early detection is crucial for patients to gain timely access to effective treatments. The AD-Detect Beta-Amyloid 4240 Ratio test fills this critical gap by providing a non-invasive and convenient screening option.